These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1616889)

  • 21. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with improved survival following surgical treatment for metastatic prostate cancer in the spine: retrospective analysis of 29 patients in a single center.
    Meng T; Chen R; Zhong N; Fan T; Li B; Yin H; Li Z; Zhou W; Song D; Xiao J
    World J Surg Oncol; 2016 Jul; 14(1):200. PubMed ID: 27472919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
    Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE
    J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.
    Petrylak DP; Scher HI; Li Z; Myers CE; Geller NL
    Cancer; 1992 Dec; 70(12):2870-8. PubMed ID: 1451069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
    Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
    Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume.
    Alhanafy AM; Zanaty F; Ibrahem R; Omar S
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):1113-1118. PubMed ID: 29699372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
    Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
    Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
    Afriansyah A; Hamid ARA; Mochtar CA; Umbas R
    Int J Urol; 2019 Jan; 26(1):83-89. PubMed ID: 30269369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract.
    Sengeløv L; Kamby C; Schou G; von der Maase H
    Cancer; 1994 Jul; 74(1):123-33. PubMed ID: 8004569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.
    Culine S; Bekradda M; Kramar A; Rey A; Escudier B; Droz JP
    Cancer; 1998 Dec; 83(12):2548-53. PubMed ID: 9874462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality.
    Reynard JM; Peters TJ; Gillatt D
    Br J Urol; 1995 Apr; 75(4):507-15. PubMed ID: 7540483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
    Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?
    Kotwal S; Whelan P
    Scand J Urol Nephrol; 2008; 42(2):116-20. PubMed ID: 17907049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA decline is an independent prognostic marker in hormonally treated prostate cancer.
    Palmberg C; Koivisto P; Visakorpi T; Tammela TL
    Eur Urol; 1999 Sep; 36(3):191-6. PubMed ID: 10450001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group.
    Mulders PF; Dijkman GA; Fernandez del Moral P; Theeuwes AG; Debruyne FM
    Cancer; 1990 Jun; 65(12):2758-61. PubMed ID: 2187588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.